SYRS


These 2 Healthcare Stocks Could Be the Next M&A Target, Says Piper Sandler

Who’s next? After Gilead snapped up Immunomedics for $21 billion in September, gaining access to Trodelvy, an antibody conjugate that could be used …

Billionaire Steven Cohen Picks up These 2 Stocks on the Dip

Stocks roared higher on Monday, but one legendary hedge fund manager isn’t breaking out the champagne just yet. Optimism that COVID-19’s spread may …

4 Biotechs to Keep an Eye on for the Annual Ash Meeting

Written by Dan Cohen and Scott Matusow from Stockmatusow.com.

Oppenheimer’s Insights: Synaptics Incorporated (SYNA), Axovant Sciences Ltd (AXON), Syros Pharmaceuticals Inc (SYRS)

Synaptics Incorporated Top Oppenheimer analyst Andrew Uerkwitz has downgraded his rating on shares of Syros Pharmaceuticals Inc (NASDAQ:SYNA) to Sell – his first …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts